News about Extivita
Back in October 2019, at Senator Cramer’s invitation, VA Secretary Robert Wilkie and the Senator toured Healing with Hyperbarics of North Dakota, a Fargo-based HBOT clinic. Cramer states, “The primary point of the federal government is the defense of our nation. Part...
One of the largest hyperbaric treatment centers in the world, The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, announced exciting results from a recent study; leading the medical industry to believe that a HBOT protocol could indeed be...
Research Triangle Park, NC (January 21, 2020) - Congressman Andy Biggs (AZ-05) and Senator Kevin Cramer (R-ND) recently introduced the TBI and PTSD Treatment Act [House Bill 4370; Senate Bill 2504], in late 2019 to direct the Veterans Administration (VA) to furnish...
Sudden sensorineural hearing loss (SSNHL), also known as sudden deafness, is hearing loss that is not caused by trauma - like a firecracker exploding next to your ear. It is an unexplained and rapid hearing loss that can happen overnight. SSNHL is marked by...
One of the earliest documented cases of HBOT to treat complications of Crohn’s disease (CD) was in 1989. It was a woman with "severe perineal CD that defied medical therapy for eight years". In this particular case the woman was treated with HBOT over a course...
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.
CINCINNATI (WKRC)Â - Suicide among our members of the military and our veterans is now at its highest level ever, reaching an average of 24 deaths a day. Several scientific and medical studies link many of these suicides to physical brain damage suffered by combat...
Many Oklahomans suffer from debilitating conditions resulting from head trauma. Brain injuries may result from active duty military service, sports activities, automobile accidents, and from a host of other traumatic events. State Rep. Jay Steagall (R-Yukon), chair of...